Business news – Page 90
-
Business
Ups and downs for erectile dysfunction drugs
First new drug in a decade approved in Europe as Viagra patent expires
-
Business
NHS to offer breast cancer prevention drugs
Five-year course of tamoxifen or raloxifene recommended for high risk women
-
-
BusinessAstraZeneca announces new UK hub
Restructuring will see all AstraZeneca R&D at new location close to University of Cambridge research
-
Business
Companies urged to publish hidden clinical trial data
Researchers could acquire data and publish themselves if firms refuse
-
Business
GSK fires Chinese R&D head in data investigation
Company is retracting a 2010 study in which data were ‘misrepresented’
-
Business
Pfizer and Takeda win $2.15bn in patent payout
Teva and Sun fined for selling generics before patent expiry
-
Business
Big data to sniff out drug marketing fraud
US Food and Drug Administration wants to track promotional spending to spot off-label marketing
-
Business
Industry reaches registration deadline
Data on thousands more chemicals submitted under Reach regulations
-
BusinessLaboratory safety goes digital
Online video resources aim to bring industry culture to academic labs
-
Business
Japanese pharma opens compound vaults
Molecule libraries to be screened for neglected diseases
-
Business
Two new ‘personalised’ cancer drugs approved
Suitable patients for GSK’s melanoma treatments must be identified using an accompanying genetic test
-
Business
Carbon capture and storage labelled ‘farcical’
Advocacy group report highlights failings in European policy over carbon emissions
-
BusinessIndustry applauds US chemical reform bill
Trade groups call the bipartisan bill an effective compromise, but environmental groups say it is too weak
-
Business
Waste CO2-derived plastic hits tonne scale
Novomer turns emissions from ammonia plant into polymers
-
OpinionCompulsory licences: necessity or threat?
Are compulsory licences for patent-protected drugs a necessary measure, or a threat to innovation?
-
Business
$500m fine over generics fraud for Ranbaxy
Company has pleaded guilty to fabricating data and producing substandard drugs